4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]-1-butanol is a key chemical intermediate in the development of targeted cancer therapies. Its core structure features a diphenylpyrazine moiety linked to an isopropylamino butanol chain. This specific scaffold is designed to function as a ligand for certain protein targets of interest. This compound is primarily utilized in the research and synthesis of novel anti-cancer agents, particularly within the field of targeted protein degradation. It serves as a crucial building block for the construction of Proteolysis-Targeting Chimeras (PROTACs). In this role, the molecule acts as the "warhead" or target protein ligand, which is then conjugated via its terminal hydroxyl group to an E3 ubiquitin ligase recruiter using a linker. This bifunctional molecule facilitates the selective degradation of oncogenic proteins. The development of such intermediates is a significant area in medicinal chemistry for creating therapies against cancers that are resistant to traditional inhibitors. Its application is highly specialized within preclinical drug discovery for hematological and solid tumors.